BWAY vs. PLSE, MDXG, KMTS, INMD, IRMD, EMBC, TNDM, AXGN, BBNX, and SIBN
Should you be buying Brainsway stock or one of its competitors? The main competitors of Brainsway include Pulse Biosciences (PLSE), MiMedx Group (MDXG), Kestra Medical Technologies (KMTS), InMode (INMD), iRadimed (IRMD), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), Beta Bionics (BBNX), and SiBone (SIBN). These companies are all part of the "medical equipment" industry.
Brainsway vs. Its Competitors
Pulse Biosciences (NASDAQ:PLSE) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
Pulse Biosciences currently has a consensus price target of $22.00, suggesting a potential upside of 41.57%. Brainsway has a consensus price target of $18.00, suggesting a potential upside of 15.68%. Given Pulse Biosciences' higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Brainsway.
In the previous week, Brainsway had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 5 mentions for Brainsway and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.36 beat Brainsway's score of 0.80 indicating that Pulse Biosciences is being referred to more favorably in the media.
77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 71.5% of Pulse Biosciences shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Brainsway has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.
Pulse Biosciences has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.
Brainsway has a net margin of 11.60% compared to Pulse Biosciences' net margin of 0.00%. Brainsway's return on equity of 8.97% beat Pulse Biosciences' return on equity.
Summary
Brainsway beats Pulse Biosciences on 9 of the 15 factors compared between the two stocks.
Get Brainsway News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainsway Competitors List
Related Companies and Tools
This page (NASDAQ:BWAY) was last updated on 9/1/2025 by MarketBeat.com Staff
